Financial Consulate’s Vaxcyte PCVX Stock Holding History

Financial Consulate’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.5K	Hold	250	–	–	﹤0.01%	585
2026 Q1	$14.5K	Hold	250	–	–	﹤0.01%	564
2025 Q4	$11.5K	Hold	250	–	–	﹤0.01%	587
2025 Q3	$9.01K	Buy	+250	New	+$8.28K	﹤0.01%	564

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Financial Consulate's PCVX Position: Q2 2026 in Review

Financial Consulate held its Vaxcyte (PCVX) position steady in Q2 2026 at 250 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #585.

Financial Consulate first reported a position in PCVX in Q3 2025 and has held it in 4 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Financial Consulate held 250 shares of Vaxcyte worth $14.5K as of Q2 2026.
Financial Consulate left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #585 holding.
Financial Consulate first reported a position in Vaxcyte in Q3 2025 and has held it in 4 quarters since.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.